Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat. (Q43584347)

24 November 2017

title

Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat. (English)

1 reference

24 November 2017

L Zezina

1 reference

24 November 2017

E Larsson

series ordinal

1 reference

24 November 2017

B Fellström

series ordinal

1 reference

24 November 2017

publication date

1 February 2001

1 reference

24 November 2017

published in

Transplant Immunology

1 reference

24 November 2017

1 reference

24 November 2017

1 reference

24 November 2017

page(s)

245-251

1 reference

Chronic rejection in rat aortic allografts. An experimental model for transplant arteriosclerosis

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Angiotensin induces inflammatory activation of human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Bimodal effects of angiotensin II on migration of human and rat smooth muscle cells. Direct stimulation and indirect inhibition via transforming growth factor-beta 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Ischemia-induced transplant arteriosclerosis in the rat. Induction of peptide growth factor expression

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

In vivo effect of TGF- beta 1. Enhanced intimal thickening by administration of TGF- beta 1 in rabbit arteries injured with a balloon catheter

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2801%2900028-4

7 January 2021

10.1016/S0966-3274(01)00028-4

Identifiers

DOI

1 reference

24 November 2017

1 reference